- Home
- EMO vs AUTL Comparison
EMO vs AUTL Comparison
Compare EMO & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMO | AUTL |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 851.8M | 368.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | EMO | AUTL |
|---|---|---|
| Price | $43.94 | $1.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 27.1K | ★ 3.8M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 6.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,128,000.00 |
| Revenue This Year | N/A | $658.11 |
| Revenue Next Year | N/A | $91.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 406.67 |
| 52 Week Low | $26.42 | $1.11 |
| 52 Week High | $40.17 | $2.88 |
Technical Indicators
Market Signals| Indicator | EMO | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 60.39 |
| Support Level | $43.89 | $1.46 |
| Resistance Level | $44.49 | $1.69 |
| Average True Range (ATR) | 0.68 | 0.09 |
| MACD | -0.16 | 0.03 |
| Stochastic Oscillator | 5.41 | 86.67 |
Price Performance
Historical ComparisonAbout EMO ClearBridge Energy Midstream Opportunity Fund Inc.
ClearBridge Energy Midstream Opportunity Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide long-term investors with a high level of total return with an emphasis on cash distributions. The Fund considers investments in midstream entities as those entities that provide midstream services including the gathering, transporting, processing, fractionation, storing, refining, and distribution of oil, natural gas liquids and natural gas.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.